118 - Adherence and efficiency of lipid-lowering therapy in patients with heterozygous familial hypercholesterolemia in Russia (ID 1375)
- Marat V. Ezhov, Russian Federation
- Narek A. Tmoyan, Russian Federation
- Tatiana A. Rozhkova, Russian Federation
- Dmitrii V. Duplyakov, Russian Federation
- Vladimir A. Salchenko, Russian Federation
- Mikhail A. Kachkovskii, Russian Federation
- Igor I. Shaposhnik, Russian Federation
- Vadim V. Genkel, Russian Federation
- Victor S. Gurevich, Russian Federation
- Soreiia A. Urazgildeeva, Russian Federation
- Aleksey V. Tregubov, Russian Federation
- Maria V. Muzalevskaya, Russian Federation
- Stepan S. Bazhan, Russian Federation
- O. V. Timoshenko, Russian Federation
- I. A. Urvanceva, Russian Federation
- K. G. Kozhokar, Russian Federation
- A. A. Sokolov, Russian Federation
- V. V. Tishko, Russian Federation
- O. I. Boeva, Russian Federation
- E. V. Bolotova, Russian Federation
- A. M. Namitokov, Russian Federation
- Yu. B. Kushnareva, Russian Federation
- Tatyana Y. Kuznetsova, Russian Federation
- Victoria A. Korneva, Russian Federation
- D. Y. Bogdanov, Russian Federation
- E. E. Chichina, Russian Federation
- V. M. Soloviev, Russian Federation
- A. I. Ershova, Russian Federation
- Alexey N. Meshkov, Russian Federation
- V. I. Makogonenko, Russian Federation
- Albert S. Galyavich, Russian Federation
- Dinara I. Sadykova, Russian Federation
- B. V. Pomogaybo, Russian Federation
- Olga L. Barbarash, Russian Federation
- V. V. Kashtalap, Russian Federation
- E. A. Shutemova, Russian Federation
- I. G. Isaeva, Russian Federation
- R. A. Khokhlov, Russian Federation
- Valentin E. Oleynikov, Russian Federation
- Irina V. Avdeeva, Russian Federation
- Ulyana V. Chubykina, Russian Federation
- Svetlana A. Bliznyuk, Russian Federation
- Asiiat S. Alieva, Russian Federation
- V. V. Ovsyannikova, Russian Federation
- G. I. Furmenko, Russian Federation
- T. M. Chernykh, Russian Federation
- Olga E. Abashina, Russian Federation
- A. R. Djanibekova, Russian Federation
- Eugenia S. Slastnikova, Russian Federation
- Liliia F. Galimova, Russian Federation
- P. D. Duplyakova, Russian Federation
- V. O. Konstantinov, Russian Federation
- Mikhail I. Voevoda, Russian Federation
Abstract
Background and Aims
The aim of the present analysis of RENAISSANCE registry (Registry of patients with familial hypercholesterolemia (FH) and very high cardiovascular risk with lack of efficiency of lipid-lowering therapy) is the assessment of adherence and efficiency of the lipid-lowering therapy of patients with FH.
Methods
The RENAISSANCE Registry is an open, multicenter, observational study and includes patients with heterozygous and homozygous FH, as well as patients with very high cardiovascular risk who did not achieve target level of LDL-cholesterol. Risk factors of atherosclerosis, history of cardiovascular diseases, diet and lipid-lowering therapy adherence were assessed.
Results
At present the Registry includes 1443 FH patients and in current analysis we have taken 899 (62%) patients with definite and probable heterozygous FH according to Dutch Lipid Clinic Network criteria (mean age 53.6±13.0 years, 56% women). At inclusion 229 (25%) patients had any of cardiovascular events (myocardial infarction, stroke, transitory ischemic attack, revascularization), and median and interquartile levels of total and LDL-cholesterol were 8.5 [7.0; 10;0] and 6.3 [4.5; 7.5] mmol/L, respectively. Lipid-lowering drugs were taken by 604 (67%) patients as follows: statins by 705 (78%), ezetimibe by 145 (16%), PCSK9 inhibitors by 30 (3%) patients. At follow-up levels of total and LDL-cholesterol decreased by 26% and 39% to 6.3 [5.0; 8;4] and 3.9 [3.0; 5.7] mmol/L, respectively. LDL-cholesterol level below 1.8 mmol/L was achieved only in 3% patients.
Conclusions
The registry data demonstrate both low adherence and low LDL-cholesterol target achievement rates in FH patients in Russia.
